Theses

On this page you find the theses, produced in the last years by the departement of Clinical Pharmacy and Toxicology. 

November 2018:

Improving acceptance of pharmacogenetic testing in patient care
Paul Bank




September 2018:

Individualized dosing of fluoropyrimidines by genotyping and phenotyping of dihydropyrimidine dehydrogenase
Linda Henricks






Mei 2018:

Optimization of sunitinib treatment in metastatic renal cell carcinoma: pharmacogenetic evidence and challenges
Liu, X



Januari 2018:

Translation of academic medicinal products towards clinical practice
Sofieke de Wilde 



September 2017:

Pharmacogenetics of sunitinib in metastatic renal cell carcinoma

Meta Diekstra cum laude




Juni 2017:

Pharmaceutical pictograms for low-literate medication users
Mara van Beusekom



December 2016:

Pharmacogenetics of osteosarcoma treatment
Hanneke Vos



November 2016:

DPD screening to prevent toxicity in fluoropyrimidine treated patients
Staveren, M.C. van




January 2016:

The role of clinical pharmacology and pharmacogenetics in electroconvulsive therapy: from safety to efficacy
Hooman Mirzakhani




Oktober 2015:

Dose optimization of oral targeted therapies in oncology
Djoeke de Wit




Oktober 2015:

Phenotyping in oncology
Frans Luitzen Opdam





Juli 2015:

proefschriftomslag Lisanne KrensRefining EGFR-monoclonal antibody treatment in colorectal cancer
Lisanne Krens








Juni 2015:

proefschrift omslag Lieke van HuisPharmacogenetics of capecitabine and oxaliplatin in treatment of advanced colorectal cancer
Lieke van Huis-Tanja





Maart 2015:

cover thesis Melanie HagleitnerMelanie Margaretha Hagleitner
The role of pharmacogenetics in Osteosarcoma






November 2014:

Dirk Jan Moes
Optimizing immunosuppression with mTOR inhibitors in renal transplant recipients





Oktober 2014:

Cover proefschrift Rodney RosarioRodney Alexander Rosalia
Particulate based vaccines for cancer immunotherapy







proefschriftomslag Marloes ten BrinkSeptember 2014:

Marloes ten Brink
Individualized therapeutics in allogenic stem cell transplantation 






September 2014:

Marije Slingerland
Exploring novel formulations and new classes of anticancer drugs in solid tumors






Mei 2014:

Mirjam Kristien Rommers
Clinical rules in hospital pharmacy practice to prevent adverse drug events






Oktober 2013:

Vincent DezentjƩ
Tamoxifen metabolism and pharmacogenetics in breast cancer






Januari 2012:

Dyah Aryani Perwitasari
Pharmacogenetics of Antiemetics in Indonesian Cancer Patients






December 2011:

Jesse Swen
Translating pharmacogenetics to primary care






Juni 2011:

Jan Pander
Pharmacogenetics of advanced colorectal cancer treatment






April 2011:

Rogier Press
Individualized dosing of calcineurin inhibitors on renal transplantation






thesis Maarten ZandvlietMaart 2011:

Maarten L. Zandvliet
Adoptive immunotherapy for viral infections after allogeneic stem cell transplantation






thesis E.R. KoomenSeptember 2010:

E.R. Koomen. 
Drug effects on melanoma.






thesis P.H. van ErpDecember 2009:

P.H. (Petronella Huberta) van Erp. 
Clinical Pharmacology of the Tyrosine Kinase Inhibitors Imatinib and Sunitinib.





thesis Wouter KooloosDecember 2009:

W.M. Kooloos (Wouter Michiel). 
Potential role of pharmacogenetics for optimalization of drug therapy in rheumatoid arthritis.





November 2009:

N. (Neeltje) Steeghs. 
Targeted therapy in oncology: mechanisms and toxicity





thesis D.M. Kweekel

Mei 2009:

D.M. (Dina Maria) Kweekel. 
Pharmacogenetics of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer




thesis Ali Vahidnia

Februari 2008:

Ali Vahidnia. 
Studies into the mechanisms of arsenic-induced neurotoxicity.





Oktober 2007:

J.A.M. (Judith Anne-Marie) Wessels. 
Pharmacogenetics of methotrexate in patients with Rheumatoid Arthritis.





September 2007:

K.J.M. (Kirsten Johanna Maria) Schimmel. 
The cytotoxic drug Cyclo-Pentenyl Cytosine: from manufacturing to anti-tumor activity and (cardio)toxicity.





thesis A. de JongJanuari 2005:

A. (Annemieke) de Jong. 
T cell immunity against early antigens of human papillomavirus type 16.